The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IκBα-deficient diffuse large B-cell lymphoma cell line

Cancer Letters

Volumn 241, Issue 1, 2006, Pages 69-78

  Liang, Mei Chih ^a   Bardhan, Sujata ^a,b   Porco, John A ^a,b   Gilmore, Thomas D ^a,b  

^a Boston University   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Epoxyquinoid; Epoxyquinone A monomer; Jesterone dimer; Lymphoma; NF kappaB; REL

Indexed keywords

ALKENE; DNA; EPOXIDE; EPOXYQUINONE A; I KAPPA B; JESTERONE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PRIMER DNA; QUINONE DERIVATIVE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL DIVISION; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENETICS; HISTIOCYTIC LYMPHOMA; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ALKENES; APOPTOSIS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; DNA, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPOXY COMPOUNDS; HUMANS; I-KAPPA B PROTEINS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; QUINONES;

EID: 39049178095     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.004     Document Type: Article

References (43)

1. Loop T., Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Nuclear Factor κB: Regulation and Role in Disease 2003, 1-48. Kluwer Academic Publishers, Amsterdam. R. Beyaert (Ed.).
2. Hayden M.S., Ghosh S. Signaling to NF-κB. Genes Dev. 2004, 18:2195-2224.
3. Tak P.P., Firestein G.S. NF-κB: a key role in inflammatory disease. J. Clin. Invest. 2001, 107:7-11.
4. Gilmore T.D., Gapuzan M.-E., Kalaitzidis D., Starczynowski D. Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer. Cancer Lett. 2002, 181:1-9.
5. Kumar A., Takada Y., Boriek A.M., Aggarwal B.B. Nuclear factor-κB: its role in health and disease. J. Mol. Med. 2004, 82:434-448.
6. Gilmore T.D., Kalaitzidis D., Liang M.-C., Starczynowski D.T. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 2004, 23:2275-2286.
7. Wood K.M., Roff M., Hay R.T. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB. Oncogene 1998, 16:2131-2139.
8. Cabannes E., Khan G., Aillet F., Jarrett R.F., Hay R.T. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene 1999, 18:3063-3070.
9. Emmerich F., Meiser M., Hummel M., Demel G., Foss H.-D., Jundt F., et al. Overexpression of IκBα without inhibition of NF-κB activity and mutations in the IκBα gene in Reed-Sternberg cells. Blood 1999, 94:3129-3134.
10. Jungnickel B., Staratschek-Jox A., Bräuninger A., Spieker T., Wolf J., Diehl V., et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J. Exp. Med. 2000, 191:395-402.
11. Mathas S., Lietz A., Janz M., Hinz M., Jundt F., Scheidereit C., et al. Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood 2003, 102:1028-1034.
12. Kalaitzidis D., Davis R.E., Rosenwald A., Staudt L.M., Gilmore T.D. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway. Oncogene 2002, 21:8759-8768.
13. Kwok B.H.B., Koh B., Ndubuisi M.I., Elofsson M., Crews C.M. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem. Biol. 2001, 8:759-766.
14. Haridas V., Arntzen C.J., Gutterman J.U. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-κB by inhibiting both its nuclear localization and ability to bind DNA. Proc. Natl Acad. Sci. USA 2001, 98:11557-11562.
15. Ojo-Amaize E.A., Kapahi P., Kakkanaiah V.N., Takahashi T., Shalom-Barak T., Cottam H.B., et al. Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IκB kinase. Cell. Immunol. 2001, 209:149-157.
16. Yang F., Oz H.S., Barve S., de Villiers W.J.S., McClain C.J., Varilek G.W. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-κB activation by inhibiting IκB kinase activity in the intestinal epithelial cell line IEC-6. Mol. Pharmacol. 2001, 60:528-533.
17. Cárcamo J.M., Pedraza A., Bórquez-Ojeda O., Zhang B., Sanchez R., Golde D.W. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IκBα kinase β. Mol. Cell. Biol. 2004, 24:6645-6652.
18. Ariga A., Namekawa J., Matsumoto N., Inoue J., Umezawa K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 2002, 277:24625-24630.
19. Liang M.-C., Bardhan S., Li C., Pace E.A., Porco J.A., Gilmore T.D. Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor κB by inhibiting the inhibitor of κB kinase. Mol. Pharmacol. 2003, 64:123-131.
20. Li C., Bardhan S., Pace E.A., Liang M.-C., Gilmore T.D., Porco J.A. Angiogenesis inhibitor epoxyquinol A: total synthesis and inhibition of transcription factor NF-κB. Org. Lett. 2002, 4:3267-3270.
21. M.-C. Liang, S. Bardhan, E.A. Pace, D. Rosman, J.A. Beutler, J.A. Porco Jr., et al., Inhibition of transcription factor NF-κB signaling proteins IKKβ and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity, Biochem. Pharmacol., in press.
22. Hu Y., Li C., Kulkarni B.A., Strobel G., Lobkovsky E., Torczynski R.M., et al. Exploring chemical diversity of epoxyquinoid natural products: synthesis and biological activity of (-)-jesterone and related molecules. Org. Lett. 2001, 3:1649-1652.
23. Kikuchi E., Horiguchi Y., Nakashima J., Kuroda K., Oya M., Ohigashi T., et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res. 2003, 63:107-110.
24. Starenki D.V., Namba H., Saenko V.A., Ohtsuru A., Maeda S., Umezawa K., et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin. Clin. Cancer Res. 2004, 10:6821-6829.
25. Matsumoto N., Ariga A., To-e S., Nakamura H., Agata N., Hirano S.-i., et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 2000, 10:865-869.
26. Watanabe M., Dewan M.Z., Okamura T., Sasaki M., Itoh K., Higashihara M., et al. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int. J. Cancer 2005, 114:32-38.
27. Ohsugi T., Hone R., Kumasaka T., Ishida A., Ishida T., Yamaguchi K., et al. In vivo antitumor activity of the NF-κB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005, 26:1382-1388.
28. Barkett M., Dooher J.E., Lemonnier L., Simmons L., Scarpati J.N., Wang Y., et al. Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3. Biochim. Biophys. Acta 2001, 1526:25-36.
29. Kalaitzidis D., Gilmore T.D. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer 2002, 34:129-135.
30. Shirra M.K., Hansen U. LSF and NTF-1 share a conserved DNA recognition motif yet require different oligomerization states to form a stable protein-DNA complex. J. Biol. Chem. 1998, 273:19260-19268.
31. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001, 194:1861-1874.
32. Glineur C., Davioud-Charvet E., Vandenbunder B. The conserved redox-sensitive cysteine residue of the DNA-binding region in the c-Rel protein is involved in the regulation of the phosphorylation of the protein. Biochem. J. 2000, 352:583-591.
33. García-Piñeres A.J., Castro V., Mora G., Schmidt T.J., Strunck E., Pahl H.L., et al. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 2001, 276:39713-39720.
34. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl Acad. Sci. USA 2000, 97:4844-4849.
35. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 2001, 276:35530-35536.
36. Lee J.H., Koo T.H., Hwang B.Y., Lee J.J. Kaurane diterpene, kamebakaurin, inhibits NF-κB by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. J. Biol. Chem. 2002, 277:18411-18420.
37. Xia Y.F., Ye B.Q., Li Y.D., Wang J.G., He X.J., Lin X., et al. Andrographolide attenuates inflammation by inhibition of NF-κB activation through covalent modification of reduced cysteine 62 of p50. J. Immunol. 2004, 173:4207-4217.
38. Park M.H., Song H.S., Kim K.H., Son D.J., Lee S.H., Yoon D.Y., et al. Cobrotoxin inhibits NF-κB activation and target gene expression through reaction with NF-κB signal molecules. Biochemistry 2005, 44:8326-8336.
39. Matthews J.R., Wakasugu N., Virelizier J.-L., Yodoi J., Hay R.T. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulfide bond involving cysteine 62. Nucleic Acids Res. 1992, 20:3821-3830.
40. Ghosh G., Duyne G.V., Ghosh S., Sigler P.B. Structure of NF-κB homodimer bound to a κB site. Nature 1995, 373:303-310.
41. Chen Y.Q., Ghosh S., Ghosh G. A novel recognition mode by the NF-κB p65 homodimer. Nat-Struct. Biol. 1998, 5:67-73.
42. Huang D.-B., Chen Y.-Q., Ruetsche M., Phelps C.B., Ghosh G. X-ray crystal structure of proto-oncogene product c-Rel bound to the CD28 response element of IL-2. Structure 2001, 9:669-678.
43. Tatetsu H., Okuno Y., Nakamura M., Matsuno F., Sonoki T., Taniguchi I., et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner. Mol. Cancer Ther. 2005, 4:1114-1120.